|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:protease_inhibitor
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AF06
|
|
gptkbp:brand
|
gptkb:Epzicom
gptkb:Kivexa
gptkb:Trizivir
gptkb:Ziagen
|
|
gptkbp:CASNumber
|
136470-78-5
|
|
gptkbp:category
|
gptkb:antiviral_drug
gptkb:WHO_essential_medicine
|
|
gptkbp:contraindication
|
HLA-B*5701 positive
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo_Wellcome
|
|
gptkbp:eliminationHalfLife
|
1.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C14H18N6O
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:meltingPoint
|
165-167°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
441300
390849
CHEMBL121
DB01048
|
|
gptkbp:riskFactor
|
hepatomegaly
lactic acidosis
hypersensitivity syndrome
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fever
nausea
vomiting
rash
hypersensitivity reaction
|
|
gptkbp:synonym
|
gptkb:ABC
gptkb:abacavir_sulfate
|
|
gptkbp:UNII
|
P0A7641Z2V
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:NRTIs
gptkb:AZT
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abacavir
|